Kulpa-Eddy JA, Taylor S, Adams KM
As of 2023, no GLP-1 transdermal systems have completed Phase 3 clinical trials or received regulatory approval
The market faces growing challenges from counterfeit and compounded GLP-1 products, leading to safety risks and regulatory concerns
It is the leading cause of nephropathy and end-stage kidney disease, neuropathy, retinopathy and adult-onset blindness, non-traumatic amputation, and contributes greatly to heart disease and cardiovascular morbidity and mortality ( This meta-analysis showed that when initiated at the prediabetic stage, interventions with medications, specifically SGLT-2 inhibitors and GLP-1 receptor agonists, show promising evidence in delaying the progression of prediabetes into diabetes
Many people dont absorb B12 as well when taken orally
Are GLP-1 Injections Good for Weight Loss